Navigation Links
Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes

for toxicity. DIO-902 has been proven to be both more effective and safer than the racemic mixture in preclinical studies.

"We are delighted with the preliminary data that we have generated to date, and at the prospect of taking the leading Cortisol Synthesis Inhibitor to the next level of clinical development. DIO-902 is clearly at the head of the pack in the advancement of this exciting new drug category," commented Daniel Green, DiObex President.

"DIO-902 offers the possibility of adding a new therapy to the armamentarium which may have an impact on the underlying cause of type 2 diabetes. The prospect of significantly reducing multiple cardiac risk factors with a single drug is an extremely attractive opportunity to enhance patient compliance and convenience while reducing the need for polypharmacy," said Bernice Welles, M.D., Vice President of Development at DiObex.

DiObex plans on initiating a 16-week phase 2b dose-ranging study with DIO- 902 in mid 2007.

About DiObex

DiObex, Inc. is a San Francisco-based biopharmaceutical company founded to develop novel products for the treatment of metabolic diseases. DiObex has two products preparing to enter Phase 2b clinical development. DIO-901 is a formulation of Very Low Dose Glucagon (VLD Glucagon) for reducing or preventing of insulin induced hypoglycemia. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 is a single enantiomer of ketoconazole and is a novel cortisol synthesis inhibitor. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type-2 diabetes and cardiovascular disease. For more information, visit www.diobex.com.

CONTACT: Daniel Green of DiObex, Inc., +1-415-551-4114, dgreen@diobex.com

Web site: '"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/26/2008)...swire/ -- Children whose eyes are misaligned and p...f developing mental illness by early adulthood, ac...hed this month in Pediatrics , the official journa... The retrospective study examined the medical rec...yes) and compared them with records of children ma...
(Date:11/25/2008)... , Audio and Web Video Resources to accompany ...log. Please see the bottom of this release for det...RNewswire-USNewswire/ -- A Mayo Clinic study shows... having a stroke -- and as a result -- delay seeki...ndings appear in the current issue of Emergency Me...
(Date:11/25/2008)...swire/ -- Proteolix, Inc., a,leader in the discov...get,protein degradation pathways in cancer and au... two ongoing Phase 2 clinical trials of carfilzomi...coming 50th Annual Meeting of the,American Societ...n a new class,of specific proteasome inhibitors a...
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 1Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 2Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 1Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 1Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 1Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 2Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 4Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 5Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 6Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 7Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 8
...--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical...t of DNA vaccines,for cancers and infectious disea...calized cancers, announced today the company,deliv...esults and,new device innovations relating to its ...t the 10th Annual Meeting of the American,Society ...
...fficacy and Markers Demonstrated in Combination Tr...stCall/ --,EntreMed, Inc. , a clinical-stage pharm...y for the treatment of cancer and inflammatory,dis...from the Phase,1b study with Panzem(R) NCD (2ME2 o... (paclitaxel) in patients with metastatic,breast c...
Other Medicine Technology:Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 2Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 3Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 4Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 5Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 2Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 3Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 4
(Date:12/2/2008)...stCall/ -- Genoptix, Inc. (Nasdaq: GXDX ), a spe...nced the Company,s participation at the RBC Capita...take place at the Westin New York Hotel at Times S...ccitelli, COO and executive vice president of Geno...conference on Wednesday, December 10, beginning at...
(Date:12/2/2008).../ -- LCA-Vision Inc. (Nasdaq:, LCAV ), a leading...r the,LasikPlus(R) brand, today announced that me...nt at RBC Capital Markets, 2008 Healthcare Confere...astern time. The conference is,being held at The... archived,webcast of the event will be available ...
(Date:12/2/2008)... -- In response to the commentary entitled "Cod Li...Infections, and the Vitamin D Deficiency Epidemic"...ement experts, Nordic Naturals announced today tha...promise to consumers and actually offer healthy om...itamin A. According to Karin Yien, MD, Nordic Natu...
(Date:12/2/2008)...hcare group at Frost & Sullivan,( http://www....t it will be,hosting an interactive analyst brief... on 11 December 2008 at 3pm GMT. , (Logo: ...O ) , With most diagnostic cardiology marke...are faced with an immense challenge of keeping pro...
Breaking Medicine News(10 mins):Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2
...in Andhra Pradesh have hit on a novel method of pr...n thousands of residents opened their// newspapers...three condoms on the front page. "Earlier we dist..., through milk vendors and at pan (tobacco) shops ...
...ticals, a leading player in the Indian drug indust...d and Drug Authority (FDA) for three// of its abbr...me. Orchid will be launching this product in the... partner, Apotex, the Chennai-based company said i...
...ts are high in saturated and trans fats, a high in...ed rate of decline in thinking, learning// and mem... essential for brain development and function, an ...ole in the development of brain plaques associated...
...British Medical Journal, researchers at Oxford Uni...er cent in the consumption of common foods// conta...increase in coronary heart disease. Trans fats ar...shelf life of food and is added to most fast foods...
Other Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
...es BchiVac V-500 with Vacuum Controller V-800 Ef... switching mechanism turns V-500 on and off as nee...ing Model V-500 is a powerful PTFE membrane vacu...s. Applications Ideally suited for use with up ...
...1000 is a new addition to the powerful PTFE membra...ce pump can achieve an ultimate vacuum of 1 mbar o... with vacuum drying ovens and centrifugal vacuum c...size up to industrial size rotary evaporators Bchi...
...500 is a powerful PTFE membrane vacuum pump design...ns Ideally suited for use with up to two rotary ...ents including vacuum ovens, concentrators, gel dr...es PEEK head resistant to chemicals and heat load...
Medicine Products: